Developer docs
API playgroundTry for free, no card

Search company profiles

Galvani Bioelectronics

Full company profile

uuid000aedl

Namestring
Galvani Bioelectronics
Websiteurl
galvani.bio
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Galvani Bioelectronics is a UK-based bioelectronics company founded in 2016 and headquartered in Stevenage. The firm is developing therapeutic approaches that treat chronic illnesses by modulating electrical impulses in the body's nervous system. Its work sits at the intersection of neuroscience, device engineering, and clinical medicine, targeting conditions addressable through electrical neuromodulation rather than pharmacological intervention.

The company's core platform is built around implantable neural interface (INI) technology, combining high-channel-count hardware, wireless power delivery, closed-loop stimulation, and AI-assisted signal processing. This architecture is designed to enable minimally invasive deployment and adaptive therapy for chronic diseases. The company operates with a small team (11-50 employees) and has assembled leadership spanning clinical medicine, executive management, and principal engineering, reflecting the multi-disciplinary demands of bioelectronic therapy development.

Commercial revenue, pricing, distribution channels, and customer segments are not disclosed in available sources, indicating a pre-commercial, research-and-development-stage posture consistent with the long regulatory and clinical timelines typical of implantable medical devices. The global bioelectric medicine market is projected to grow from USD 25.48 billion in 2025 to USD 47.28 billion by 2034 (CAGR ~7.12%), providing the macro tailwind in which the company is positioned.

Short descriptiontext

Galvani Bioelectronics is a UK-based bioelectronics company founded in 2016 that develops implantable neural interface therapies to treat chronic illnesses by modulating electrical signals in the nervous system, combining hardware, wireless power, and AI signal processing.

Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersStevenage, United Kingdom
HQ citystring
Stevenage
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
bioelectronic medicine, neural stimulation therapy, implantable medical devices, chronic disease treatment, electrical nerve modulation
Industry2 codes
1Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
CodeHLAHAEAKPrimaryYes
2Neurology & CNS Specialty Pharmaceuticals
CodeHLAIACACPrimaryNo
NAICS code3 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Bioelectronic Medicine
Social media profiles1 record
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Galvani Bioelectronics develops bioelectronic medicines designed to treat chronic illnesses by controlling electrical impulses in the body. The company focuses on implantable neural interface technology that reads and modulates nerve signals to address disease pathways, with the goal of providing targeted, device-based therapies for chronic conditions.

Differentiator
Functional benefit
Problem solved
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
1Nevro Corp
TypeDirect peer
Description

Nevro develops implantable spinal cord stimulation systems for chronic pain, making it a direct peer in implantable neuromodulation with overlapping clinical targets and a similar hardware-plus-software therapy model.

2Axonics
TypeDirect peer
Description

Axonics manufactures implantable sacral neuromodulation systems for incontinence, a direct peer in miniaturized, rechargeable implantable neurostimulators targeting chronic disease indications.

3Saluda Medical
TypeDirect peer
Description

Saluda Medical develops closed-loop spinal cord stimulation systems, making it one of the closest direct peers given Galvani's emphasis on closed-loop stimulation and AI-driven signal processing.

4setPoint Medical
TypeDirect peer
Description

setPoint Medical is developing implantable vagus nerve stimulation therapies for inflammatory and autoimmune diseases, a direct peer in bioelectronic medicine targeting chronic conditions beyond pain.

5ElectroCore
TypeDirect peer
Description

ElectroCore develops non-invasive vagus nerve stimulation, a closely related peer in bioelectronic/neuromodulation therapies for chronic conditions, though differentiated by its non-invasive delivery.

6Cala Health
TypeEmerging player
Description

Cala Health develops wearable neuromodulation devices for chronic disease, an emerging peer that intersects with Galvani's bioelectronic therapy approach but with a non-implantable delivery model.

7Medtronic
TypeBroad incumbent
Description

Medtronic operates the largest portfolio of implantable neuromodulation devices (SCS, DBS, VNS, intrathecal), making it the dominant broad incumbent against which Galvani must differentiate.

8Abbott
TypeBroad incumbent
Description

Abbott's Neuromodulation business (formerly St. Jude Medical) markets leading spinal cord and dorsal root ganglion stimulation systems, a broad incumbent with deep clinical and commercial reach.

9Boston Scientific
TypeBroad incumbent
Description

Boston Scientific markets the Precision and Spectra spinal cord stimulation platforms alongside deep brain stimulation systems, a broad incumbent competing across most implantable neuromodulation indications.

10LivaNova
TypeBroad incumbent
Description

LivaNova is a leading manufacturer of vagus nerve stimulation therapy for drug-resistant epilepsy and depression, a broad incumbent that overlaps directly with Galvani's bioelectronic VNS therapy direction.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Galvani Bioelectronics

Bioelectronic Medicinegalvani.bio

Galvani Bioelectronics is a UK-based bioelectronics company founded in 2016 that develops implantable neural interface therapies to treat chronic illnesses by modulating electrical signals in the nervous system, combining hardware, wireless power, and AI signal processing.

What Galvani Bioelectronics does

Galvani Bioelectronics is a UK-based bioelectronics company founded in 2016 and headquartered in Stevenage. The firm is developing therapeutic approaches that treat chronic illnesses by modulating electrical impulses in the body's nervous system. Its work sits at the intersection of neuroscience, device engineering, and clinical medicine, targeting conditions addressable through electrical neuromodulation rather than pharmacological intervention.

The company's core platform is built around implantable neural interface (INI) technology, combining high-channel-count hardware, wireless power delivery, closed-loop stimulation, and AI-assisted signal processing. This architecture is designed to enable minimally invasive deployment and adaptive therapy for chronic diseases. The company operates with a small team (11-50 employees) and has assembled leadership spanning clinical medicine, executive management, and principal engineering, reflecting the multi-disciplinary demands of bioelectronic therapy development.

Commercial revenue, pricing, distribution channels, and customer segments are not disclosed in available sources, indicating a pre-commercial, research-and-development-stage posture consistent with the long regulatory and clinical timelines typical of implantable medical devices. The global bioelectric medicine market is projected to grow from USD 25.48 billion in 2025 to USD 47.28 billion by 2034 (CAGR ~7.12%), providing the macro tailwind in which the company is positioned.

Galvani Bioelectronics firmographics

Firmographics
Name
Galvani Bioelectronics
Website
https://galvani.bio
Company type
Private
Founded year
2016
Headcount range
11–50 employees
Short description
Galvani Bioelectronics is a UK-based bioelectronics company founded in 2016 that develops implantable neural interface therapies to treat chronic illnesses by modulating electrical signals in the nervous system, combining hardware, wireless power, and AI signal processing.
Ownership category
akta.pro rank

Galvani Bioelectronics industry classification

Industry
Product category
Bioelectronic Medicine
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Surgical and Medical Instrument Manufacturing (339112)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro primary industry
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)
akta.pro secondary industry
Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

  • Bioelectronic medicine
  • Neural stimulation therapy
  • Implantable medical devices
  • Chronic disease treatment
  • Electrical nerve modulation

Where Galvani Bioelectronics is headquartered

Location

Headquarters

HQ city
Stevenage
HQ country
United Kingdom
HQ region
Europe

Markets served

Galvani Bioelectronics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Galvani Bioelectronics product offering

Product offering

Core offering

Galvani Bioelectronics develops bioelectronic medicines designed to treat chronic illnesses by controlling electrical impulses in the body. The company focuses on implantable neural interface technology that reads and modulates nerve signals to address disease pathways, with the goal of providing targeted, device-based therapies for chronic conditions.

Differentiator

Problem solved

Functional benefit

Companies that use Galvani Bioelectronics

Customer profile

Ideal customer profiles1 record

Galvani Bioelectronics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Galvani Bioelectronics partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves3 records

Expansion highlights3 records

Galvani Bioelectronics competitors and assessment

Company assessment

Direct peers

  • Nevro Corp: Nevro develops implantable spinal cord stimulation systems for chronic pain, making it a direct peer in implantable neuromodulation with overlapping clinical targets and a similar hardware-plus-software therapy model.
  • Axonics: Axonics manufactures implantable sacral neuromodulation systems for incontinence, a direct peer in miniaturized, rechargeable implantable neurostimulators targeting chronic disease indications.
  • Saluda Medical: Saluda Medical develops closed-loop spinal cord stimulation systems, making it one of the closest direct peers given Galvani's emphasis on closed-loop stimulation and AI-driven signal processing.
  • setPoint Medical: setPoint Medical is developing implantable vagus nerve stimulation therapies for inflammatory and autoimmune diseases, a direct peer in bioelectronic medicine targeting chronic conditions beyond pain.
  • ElectroCore: ElectroCore develops non-invasive vagus nerve stimulation, a closely related peer in bioelectronic/neuromodulation therapies for chronic conditions, though differentiated by its non-invasive delivery.

Emerging players

  • Cala Health: Cala Health develops wearable neuromodulation devices for chronic disease, an emerging peer that intersects with Galvani's bioelectronic therapy approach but with a non-implantable delivery model.

Broad incumbents

  • Medtronic: Medtronic operates the largest portfolio of implantable neuromodulation devices (SCS, DBS, VNS, intrathecal), making it the dominant broad incumbent against which Galvani must differentiate.
  • Abbott: Abbott's Neuromodulation business (formerly St. Jude Medical) markets leading spinal cord and dorsal root ganglion stimulation systems, a broad incumbent with deep clinical and commercial reach.
  • Boston Scientific: Boston Scientific markets the Precision and Spectra spinal cord stimulation platforms alongside deep brain stimulation systems, a broad incumbent competing across most implantable neuromodulation indications.
  • LivaNova: LivaNova is a leading manufacturer of vagus nerve stimulation therapy for drug-resistant epilepsy and depression, a broad incumbent that overlaps directly with Galvani's bioelectronic VNS therapy direction.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Galvani Bioelectronics social profiles

Digital presence

Galvani Bioelectronics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Galvani Bioelectronics leadership team

Management profile

Number of profiles

Profiles3 records

Galvani Bioelectronics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Galvani Bioelectronics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Galvani Bioelectronics

What does Galvani Bioelectronics do?

Galvani Bioelectronics develops bioelectronic medicines designed to treat chronic illnesses by controlling electrical impulses in the body. The company focuses on implantable neural interface technology that reads and modulates nerve signals to address disease pathways, with the goal of providing targeted, device-based therapies for chronic conditions.

When was Galvani Bioelectronics founded?

Galvani Bioelectronics was founded in 2016. It employs 11 to 50 people.

Where is Galvani Bioelectronics based?

Galvani Bioelectronics is headquartered in Stevenage, United Kingdom, in the Europe region.

Who are Galvani Bioelectronics's main competitors?

Direct peers on record are Nevro Corp, Axonics, Saluda Medical, setPoint Medical and ElectroCore. Cala Health is listed as an emerging player. Broad incumbents are Medtronic, Abbott, Boston Scientific and LivaNova.

Does Galvani Bioelectronics have an API?

No public API is recorded for Galvani Bioelectronics.

What industry is Galvani Bioelectronics in?

Galvani Bioelectronics's product category is Bioelectronic Medicine. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS), with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business InsiderMoncef Slaoui is retreating from the biotech industry after facing a substantiated sexual-harassment claimGSK substantiated sexual-harassment claims against Moncef Slaoui, leading to his firing from Galvani Bioelectronics and exits from Centessa, Vaxcyte, and Medicxi. Slaoui apologized and stepped back from professional responsibilities. GSK CEO Emma Walmsley said the company expects integrity from senior leaders.Business InsiderRead GSK CEO Emma Walmsley’s internal memo on the sexual harassment allegations against Moncef SlaouiGSK CEO Emma Walmsley said she was shocked and angry about sexual harassment allegations against former executive Moncef Slaoui, which an independent investigation substantiated. The company terminated Slaoui from his Galvani Bioelectronics board role and renamed its vaccines R&D center in Rockville, Maryland.BenzingaGSK Fires Moncef Slaoui Over Sexual Harassment Charges - GSK (NYSE:GSK)GlaxoSmithKline fired Moncef Slaoui as board chairman of Galvani Bioelectronics after an investigation substantiated sexual harassment allegations made by a GSK employee. The conduct occurred several years ago when Slaoui was employed at GSK, and upon receiving a letter containing the allegations in February, the GSK Board immediately initiated an investigation with an experienced law firm. Christopher Corsico, senior vice president of development at GSK and current Galvani board member, was appointed as the new chairman of Galvani Bioelectronics.PR NewswireStatement From Dr Moncef SlaouiGlaxoSmithKline plc terminated Dr. Moncef Slaoui as Chair of the Galvani Bioelectronics Board on March 24, 2021, citing his actions that put a former colleague in an uncomfortable situation. Dr. Slaoui issued a statement expressing deep regret and unconditional apologies to the employee concerned, as well as to his wife and family. He announced he is taking an immediate leave of absence from his professional responsibilities.PR NewswireToyota, ARM, VF Global et Galvani Biolelectronics inaugureront le IDTechEx Show!IDTechEx announced the agenda for its IDTechEx Show! conference scheduled for May 10–11, 2017, at the Estrel Congress Center in Berlin, featuring four cornerstone presentations from VF Global Innovation Centre, Galvani Bioelectronics, ARM, and Toyota Motor Corporation. Galvani Bioelectronics, co-founded by GlaxoSmithKline and Alphabet, has received $675 million in investment to develop bioelectronics combining biosciences and electronics for healthcare applications. The event expects over 3,000 visitors from 200 organizations showcasing emerging technologies including sensors, energy storage, electric vehicles, IoT, and 3D printing.PR NewswireToyota, ARM, VF Global and Galvani Biolelectronics to Open the IDTechEx Show!The IDTechEx Show! in Berlin, Germany on May 10-11, 2017 featured four Cornerstone Presentations from major companies opening the event, with over 3,000 attendees and 200 organizations exhibiting emerging technologies. VF Global Innovation Center presented on wearable technology for clothing brands, Galvani Bioelectronics showcased healthcare bioelectronics (co-founded by GlaxoSmithKline and Alphabet with $675 million in funding), ARM discussed IoT progress with over 95 billion chips shipped, and Toyota Motor Corporation covered mobility innovation including electric vehicles and energy independent vehicles. The event brought together global brands for technology scouting and product innovation focused on changing demographics and global megatrends.PR NewswireToyota, ARM, VF Global und Galvani Biolelectronics eröffnen die IDTechEx Show!Toyota, ARM, VF Global, and Galvani Bioelectronics are opening the IDTechEx Show in Berlin with keynote presentations on future technologies in clothing, health, IoT, and mobility. The event, scheduled for May 10-11, 2017, is expected to attract over 3,000 participants and feature 200 companies showcasing innovations such as sensors, electric vehicles, and advanced materials.PR NewswireKey Startups and Industry Figures to Present at 2016 Neurotech Leaders ForumNeurotech Reports will host the 16th annual Neurotech Leaders Forum on October 24-25, 2016, in San Francisco/Burlingame, California, featuring presentations from executives of neurotechnology companies and research organizations. Key speakers include Doug Weber from DARPA's Biological Technologies Office and Adam Roth from Galvani Bioelectronics, alongside representatives from LivaNova, St. Jude Medical, and several startups in the neurotechnology sector. The conference moves to the Embassy Suites San Francisco Airport-Waterfront location this year, with Micro Systems Technologies serving as Platinum Sponsor.FinSMEsGSK and Verily Form Galvani Bioelectronics for Development of Bioelectronic MedicinesGSK and Verily formed Galvani Bioelectronics to develop bioelectronic medicines, with GSK holding 55% equity and Verily 45%. Verily will invest up to £540m over seven years, subject to milestones. Initial work targets inflammatory, metabolic, and endocrine disorders, including type 2 diabetes.Business InsiderGoogle’s parent company wants to treat disease by zapping you with electricityVerily and GlaxoSmithKline formed Galvani Bioelectronics to develop electric signal treatments for chronic diseases like arthritis, diabetes, and asthma. GSK holds a 55% stake, Verily 45%. The UK-based company will build on existing bioelectronics research and Verily's biocompatible device experience.